Non-alcoholic fatty liver disease is not related to the incidence of diabetic nephropathy in Type 2 diabetes

International Journal of Molecular Sciences

Volumn 13, Issue 11, 2012, Pages 14698-14706

  Zhan, Yu Tao ^a   Zhang, Chuan ^b   Li, Li ^a   Bi, Chun Shan ^a   Song, Xin ^a   Zhang, Shu Tian ^c  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Diabetes; Diabetic nephropathy; Non alcoholic fatty liver disease

Indexed keywords

ALBUMIN; CHOLESTEROL; GLUCOSE; TRIACYLGLYCEROL;

ADULT; ANKLE BRACHIAL INDEX; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL FEATURE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; DISEASE DURATION; ECHOGRAPHY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; PREVALENCE; RISK FACTOR; URINARY EXCRETION; WAIST CIRCUMFERENCE; AGED; COMPLICATION; DIABETIC NEPHROPATHIES; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; RETROSPECTIVE STUDY;

AGED; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84870686035     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms131114698     Document Type: Article

References (22)

1. Reid, A.E. Nonalcoholic steatohepatitis. Gastroenterology 2001, 121, 710-7232.
2. Angulo, P. Nonalcoholic fatty liver disease. N. Engl. J. Med. 2002, 346, 1221-1231.
3. McCullough, A.J. Pathophysiology of nonalcoholic steatohepatitis. J. Clin. Gastroenterol. 2006, 40, S17-S29.
4. Starley, B.Q.; Calcagno, C.J.; Harrison, S.A. Nonalcoholic fatty liver disease and hepatocellular carcinoma: A weighty connection. Hepatology 2010, 51, 1820-1832.
5. Targher, G.; Bertolini, L.; Poli, F.; Rodella, S.; Scala, L.; Tessari, R.; Zenari, L.; Falezza, G. Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients. Diabetes 2005, 54, 3541-3546.
6. Targher, G.; Bertolini, L.; Rodella, S.; Tessari, R.; Zenari, L.; Lippi, G.; Arcaro, G. Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients. Diabetes Care 2007, 30, 2119-2121.
7. Targher, G.; Bertolini, L.; Padovani, R.; Rodella, S.; Tessari, R.; Zenari, L.; Day, C.; Arcaro, G. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care 2007, 30, 1212-1218.
8. Shibata, M.; Kihara, Y.; Taguchi, M.; Tashiro, M.; Otsuki, M. Nonalcoholic fatty liver disease is a risk factor for type 2 diabetes in middle-aged Japanese men. Diabetes Care 2007, 30, 2940-2944.
9. Adams, L.A.; Waters, O.R.; Knuiman, M.W.; Elliott, R.R.; Olynyk, J.K. NAFLD as a risk factor for the development of diabetes and the metabolic syndrome: An eleven-year follow-up study. Am. J. Gastroenterol. 2009, 104, 861-867.
10. Targher, G.; Chonchol, M.; Zoppini, G.; Abaterusso, C.; Bonora, E. Risk of chronic kidney disease in patients with non-alcoholic fatty liver disease: Is there a link? J. Hepatol. 2011, 54, 1020-1029.
11. Fugmann, T.; Borgia, B.; Révész, C.; Godó, M.; Forsblom, C.; Hamar, P.; Holthöfer, H.; Neri, D.; Roesli, C. Proteomic identification of vanin-1 as a marker of kidney damage in a rat model of type 1 diabetic nephropathy. Kidney Int. 2011, 80, 272-281.
12. Leitão, C.B.; Canani, L.H.; Bolson, P.B.; Molon, M.P.; Silveiro, S.P.; Gross, J.L. What values should be used to diagnose microalbuminuria in patients with diabetes mellitus? Arq. Bras. Endocrinol. Metabol. 2006, 50, 322-326.
13. Levin-Iaina, N.; Iaina, A.; Raz, I. The emerging role of NO and IGF-1 in early renal hypertrophy in STZ-induced diabetic rats. Diabetes Metab. Res. Rev. 2011, 27, 235-243.
14. Kumar, R.; Winocour, P.H. Dual blockade of the rennin-angiotensin system in diabetes-Rationale and risks. Br. J. Diabetes Vasc. Dis. 2005, 5, 266-271.
15. Medina, J.; Fernandez-Salazar, L.I.; Garcia-Buey, L.; Moreno-Otero, R. Approach to the pathogenesis and treatment of nonalcoholic steatohepatitis. Diabetes Care 2004, 27, 2057-2066.
16. Targher, G.; Bertolini, L.; Rodella, S.; Zoppini, G.; Lippi, G.; Day, C.; Muggeo, M. Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and proliferative/laser-treated retinopathy in type 2 diabetic patients. Diabetologia 2008, 51, 444-450.
17. Hwang, S.T.; Cho, Y.K.; Yun, J.W.; Park, J.H.; Kim, H.J.; Park, D.I.; Sohn, C.I.; Jeon, W.K.; Kim, B.I.; Rhee, E.J.; et al. Impact of NAFLD on microalbuminuria in patients with prediabetes and diabetes. Intern. Med. J. 2010, 40, 437-442.
18. Manco, M.; Ciampalini, P.; deVito, R.; Vania, A.; Cappa, M.; Nobili, V. Albuminuria and insulin resistance in children with biopsy proven non-alcoholic fatty liver disease. Pediatr. Nephrol. 2009, 24, 1211-1217.
19. Bloomgarden, Z.T. Diabetic Nephropathy. Diabetes Care 2005, 28, 745-751.
20. Lakhotia, M.; Gehlot, R.S.; Jain, P.; Sharma, S.; Singh, M. Lipoprotein(a) in Type 2 Diabetic Subjects in relation to Diabetic Microvascular Complications. JIACM 2003, 4, 304-307.
21. Farrell, G.C.; Chitturi, S.; Au, G.K.; Sollano, J.D. Asia-Pacific Working Party on NAFLD. Guidelines for the assessment and management of non-alcoholic fatty liver disease in the Asia-Pacific region: Executive summary. J. Gastroenterol. Hepatol. 2007, 22, 775-777.
22. Zeng, M.D.; Li, Y.M.; Chen, C.W.; Lu, L.G.; Fan, J.G.; Wang, B.Y.; Mao, Y.M. Guidelines for the diagnosis and treatment of alcoholic liver disease. J. Dig. Dis. 2008, 9, 113-116.